In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death

Joseph B Lerman; L Kristin Newby

doi:10.7326/J23-0012

In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death

Ann Intern Med. 2023 Apr;176(4):JC40. doi: 10.7326/J23-0012. Epub 2023 Apr 4.

Authors

Joseph B Lerman¹, L Kristin Newby¹

Affiliation

¹ Duke University School of Medicine, Division of Cardiology, Durham, North Carolina, USA (J.B.L., L.K.N.).

PMID: 37011388
DOI: 10.7326/J23-0012

Abstract

Kalra PR, Cleland JG, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. 36347265.

Publication types

Comment

MeSH terms

Anemia, Iron-Deficiency* / complications
Anemia, Iron-Deficiency* / drug therapy
Heart Failure* / complications
Heart Failure* / drug therapy
Hospitalization
Humans
Iron Deficiencies*
Maltose / therapeutic use
Prospective Studies

Substances

ferric derisomaltose
Maltose